Trials / Completed
CompletedNCT02175121
Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of Pf-06291874 Given As Monotherapy To Adults With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 172 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is going to assess the safety and tolerability of PF-06291874 in adults with Type 2 Diabetes Mellitus as monotherapy, to evaluate the significance of overall glycemic control in these subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Tablet, once daily for 28 days |
| DRUG | PF-06291874 | Tablet, 15 mg, once daily for 28 days |
| DRUG | PF-06291874 | Tablet, 35 mg, once daily for 28 days |
| DRUG | PF-06291874 | Tablet, 75 mg, once daily for 28 days |
| DRUG | PF-06291874 | Tablet, 150 mg, once daily for 28 days |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2015-03-01
- Completion
- 2015-03-01
- First posted
- 2014-06-26
- Last updated
- 2016-06-15
- Results posted
- 2016-06-15
Locations
19 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02175121. Inclusion in this directory is not an endorsement.